Bronchodilator treatment for COPD in primary care of four Latin America countries: The multinational, cross-sectional, non-interventional PUMA study

Pulmonary Pharmacology and Therapeutics

Volumn 38, Issue , 2016, Pages 10-16

  Montes de Oca, María ^a   Lopez Varela, María Victorina ^b   Jardim, Jose ^c   Stirvulov, Roberto ^d   Surmont, Filip ^e  

^a HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Bronchodilator; COPD; Primary care; PUMA; Treatment

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; SHORT ACTING DRUG; DELAYED RELEASE FORMULATION;

ADULT; ARTICLE; CENTRAL AMERICA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SOUTH AMERICA; SPIROMETRY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DELAYED RELEASE FORMULATION; MIDDLE AGED; MULTICENTER STUDY; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SOUTH AND CENTRAL AMERICA; VITAL CAPACITY;

ADRENAL CORTEX HORMONES; ADULT; BRONCHODILATOR AGENTS; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LATIN AMERICA; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; VITAL CAPACITY;

EID: 84964452496     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2016.04.002     Document Type: Article

References (25)

1. Vestbo J., Hurd S.S., Agustí A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013, 187:347-365.
2. Montes de Oca M., López Varela M.V., Acuña A., Schiavi E., Rey M.A., Jardim J., et al. ALAT-2014 chronic obstructive pulmonary disease (COPD) clinical practice guidelines: questions and answers. Arch. Bronconeumol 2015, 51:403-416.
3. National Institute for Health and Care Excellence NICE Guidelines [CG101]: Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (Partial Update) 2010, National Institute for Health and Care Excellence, London, Available from:, (accessed 15.02.16). http://www.nice.org.uk/guidance/cg101.
4. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch. Bronconeumol 2014, 50(Suppl. 1):1-16.
5. Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013, 9. CD009552.
6. Beeh K.M., Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther. 2010, 27:150-159.
7. Appleton S., Jones T., Poole P., Pilotto L., Adams R., Lasserson T.J., et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006, 3. CD006101.
8. Jones R.C., Dickson-Spillmann M., Mather M.J., Marks D., Shackell B.S. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir. Res. 2008, 9:62.
9. Price D., West D., Brusselle G., Gruffydd-Jones K., Jones R., Miravitlles M., et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int. J. Chron. Obstruct. Pulmon. Dis. 2014, 9:889-904.
10. Franssen F.M., Spruit M.A., Wouters E.F. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2011, 6:493-501.
11. Bourbeau J., Sebaldt R.J., Day A., Bouchard J., Kaplan A., Hernandez P., et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can. Respir. J. 2008, 15:13-19.
12. Make B., Dutro M.P., Paulose-Ram R., Marton J.P., Mapel D.W. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2012, 7:1-9.
13. Ingebrigtse T.S., Marott J.L., Vestbo J., Hallas J., Nordestgaard B.G., Dahl M., et al. Characteristics of undertreatment in COPD in the general population. Chest 2013, 144:1811-1818.
14. Foster J.A., Yawn B.P., Maziar A., Jenkins T., Rennard S.I., Casebeer L. Enhancing COPD management in primary care settings. Med. Gen. Med. 2007, 9:24.
15. Schiavi E., Stirbulov R., Hernández Vecino R., Mercurio S., Di Boscio V., Puma Team COPD screening in primary care in four Latin American countries: methodology of the PUMA Study. Arch. Bronconeumol. 2014, 50:469-474.
16. López Varela M.V., Muiño A., Pérez Padilla R., Jardim J.R., Tálamo C., Montes de Oca M., et al. Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study. Arch. Bronconeumol. 2008, 44:58-64.
17. López Varela M.V., Montes de Oca M., Rey A., Casas A., Stirbulov R., Di Boscio V. Opportunistic COPD case-finding in primary care of four Latin America countries. Developing a simple screening tool: the PUMA study. Respirology 2016, (in press).
18. Perez X., Wisnivesky J.P., Lurslurchachai L., Kleinman L.C., Kronish I.M. Barriers to adherence to COPD guidelines among primary care providers. Respir. Med. 2012, 106:374-381.
19. Salinas G.D., Williamson J.C., Kalhan R., Kalhan R., Thomashow B., Scheckermann J.L., et al. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int. J. Chron. Obstruct. Pulmon. Dis. 2011, 6:171-179.
20. Jochmann A., Neubauer F., Miedinger D., Schafroth S., Tamm M., Leuppi J.D. General practitioners adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss. Med. Wkly. 2010, Epub April 21.
21. Lucas A.E., Smeenk F.W., Smeele I.J., van Schayck C.P. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam. Pract. 2008, 25:86-91.
22. Decramer M., Bartsch P., Pauwels R., Yernault J.C. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch. Chest Dis. 2003, 59:62-80.
23. Glaab T., Banik N., Rutschmann O.T., Wencker M. National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD 2006, 3:141-148.
24. Corrado A., Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir. Med. 2012, 106:989-997.
25. Asche C.V., Leader S., Plauschinat C., Raparla S., Yan M., Ye X., Young D. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int. J. Chron. Obstruct. Pulmon. Dis. 2012, 7:201-209.